drugset / Trial / NCT02694770
A Study Evaluating the Efficacy and Safety of Neihulizumab vs "Conventional Treatment" to Treat Sr-aGvHD
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is to assess the efficacy of Neihulizumab versus "conventional therapy" and to evaluate safety, pharmacokinetics and immunogenicity in treating steroid-refractory acute Graft-vs-Host Disease
Timeline
- Start
- 2016-07
- Primary completion
- 2017-09
- Completion
- 2018-02
Outcome
Outcome not reported
Stopped: “corporate decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Neihulizumab | Monoclonal antibody | — | Intravenous |
| Comparator | Alemtuzumab | Monoclonal antibody | — | — |
| Comparator | Basiliximab | Monoclonal antibody | — | — |
| Comparator | Daclizumab | Monoclonal antibody | — | — |
| Comparator | Etanercept | Protein / enzyme biologic | — | — |
| Comparator | Infliximab | Monoclonal antibody | — | — |
| Comparator | Inolimomab | Monoclonal antibody | — | — |
| Comparator | Methotrexate | Small molecule | — | — |
| Comparator | Mycophenolate Mofetil | Small molecule | — | — |
| Comparator | Pentostatin | Small molecule | — | — |
| Comparator | Sirolimus | Small molecule | — | — |
| Comparator | denileukin diftitox | Protein / enzyme biologic | — | — |